News Image

Should you consider NASDAQ:IRMD for quality investing?

By Mill Chart

Last update: Aug 22, 2023

In this article we will dive into IRADIMED CORP (NASDAQ:IRMD) as a possible candidate for quality investing. Investors should always do their own research, but we noticed IRADIMED CORP showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.

What matters for quality investors.

  • Over the past 5 years, IRADIMED CORP has experienced impressive revenue growth, with 18.22% increase. This demonstrates the company's ability to effectively expand its top line and suggests a positive outlook for future revenue generation.
  • The ROIC excluding cash and goodwill of IRADIMED CORP stands at 58.86%, reflecting the company's strong financial management and profitability. This metric underscores its ability to generate favorable returns on the capital invested in its core operations.
  • With a favorable Debt/Free Cash Flow Ratio of 0.0, IRADIMED CORP showcases its sound financial discipline and cash flow management. This ratio indicates the company's ability to service its debt obligations while maintaining sufficient free cash flow for future investments or operational needs.
  • The Profit Quality (5-year) of IRADIMED CORP stands at 154.0%, highlighting its ability to consistently generate reliable profits. This metric underscores the company's strong business fundamentals and reinforces its position as a financially stable entity.
  • IRADIMED CORP has consistently achieved strong EBIT growth over the past 5 years, with a 64.69% increase. This underscores the company's effective management of its operating income and suggests a positive outlook for future profitability.
  • IRADIMED CORP has achieved superior EBIT 5-year growth compared to its Revenue 5-year growth. This demonstrates the company's ability to maximize its profitability through effective cost management and operational strategies.

What is the full fundamental picture of NASDAQ:IRMD telling us.

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 205 industry peers in the Health Care Equipment & Supplies industry. IRMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IRMD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make IRMD suitable for growth and quality investing!

For an up to date full fundamental analysis you can check the fundamental report of IRMD

More ideas for quality investing can be found on ChartMill in our Caviar Cruise screen.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

IRADIMED CORP

NASDAQ:IRMD (4/22/2024, 7:08:51 PM)

After market: 42.36 0 (0%)

42.36

+1.36 (+3.32%)

IRMD News

News Imagea month ago - iRadimed CorporationIRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
News Imagea month ago - iRadimed CorporationIRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference...

News Image2 months ago - Market News VideoiRadimed (IRMD) Shares Cross Above 200 DMA
News Image2 months ago - iRadimed CorporationIRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
News Image2 months ago - iRadimed CorporationIRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results

Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP...

News Image3 months ago - iRadimed CorporationIRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
News Image3 months ago - iRadimed CorporationIRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.

WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth...

News Image3 months ago - Investor's Business DailyBruker Stock Rising, Near Buy Point; Gets Rating Upgrade

A Relative Strength Rating upgrade for Bruker stock shows improving technical performance. Will it continue?

News Image3 months ago - Market News VideoCommit To Purchase iRadimed At $29.52, Earn 3.9% Annualized Using Options
News Image3 months ago - iRadimed CorporationIRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
News Image3 months ago - iRadimed CorporationIRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue

Reports preliminary fourth quarter 2023 revenue of $17.5 million WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) --  IRADIMED CORPORATION (the...

News Image4 months ago - iRadimed CorporationIRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
IRMD Links
Follow us for more